Ep300 - E1A binding protein p300 Gene

中文名称：E1A 结合蛋白 p300

种属: Rattus norvegicus

基因 ID: 170915 | 基因类型: protein coding

关于 Ep300

Primary_assembly 7: 113,106,247-113,178,529 forward strand.mRatBN7.2:CM026980.1

This gene has 1 transcript (splice variant), 285 orthologues, 2 paralogues and is associated with 72 phenotypes. Biased expression in Spleen (RPKM 141.5), Thymus (RPKM 139.8) and 9 other tissues.

功能概要

该基因编码的蛋白可启动多种功能，包括 DNA 结合活性； DNA结合转录因子结合活性；和 p53 结合活性。参与多个过程，包括细胞对有机环状化合物的反应；细胞分化的正调控；蛋白质代谢过程的调控。位于染色质；细胞质；和核。蛋白质-DNA 复合物的一部分。用于研究糖尿病视网膜病变和膜增生性肾小球肾炎。先天性膈疝的生物标志物；心脏疾病;肝细胞癌；高血压;和短暂性脑缺血。该基因的人类直系同源物与 Rubinstein-Taybi 综合征有关；结直肠癌；和充血性心力衰竭。与人 EP300（E1A 结合蛋白 p300）同源。 [由基因组资源联盟提供，2022 年 4 月]

Enables several functions, including DNA binding activity; DNA-binding transcription factor binding activity; and p53 binding activity. Involved in several processes, including cellular response to organic cyclic compound; positive regulation of cell differentiation; and regulation of protein metabolic process. Located in chromatin; cytoplasm; and nucleus. Part of protein-DNA complex. Used to study diabetic retinopathy and membranoproliferative glomerulonephritis. Biomarker of congenital diaphragmatic hernia; heart disease; hepatocellular carcinoma; hypertension; and transient cerebral ischemia. Human ortholog(s) of this gene implicated in Rubinstein-Taybi syndrome; colorectal cancer; and congestive heart failure. Orthologous to human EP300 (E1A binding protein p300). [provided by Alliance of Genome Resources, Apr 2022]

Ep300 基因产物(1)

mRNA	Protein	Name
XM_039080287.1	XP_038936215.1	LOW QUALITY PROTEIN: histone acetyltransferase p300

基因本体论

分子功能
生物过程
细胞组分

分子功能 GO 注释	逻辑证据	参考文献	来源
enables DNA-binding transcription factor binding	IPI IPI: 通过物理相互作用推断	15117818	RGD
enables NF-kappaB binding	IPI IPI: 通过物理相互作用推断	17252537	RGD
enables RNA polymerase II cis-regulatory region sequence-specific DNA binding	IDA IDA: 通过直接分析推断	20702579	RGD
enables RNA polymerase II-specific DNA-binding transcription factor binding	IPI IPI: 通过物理相互作用推断	10362258	RGD
enables SMAD binding	IPI IPI: 通过物理相互作用推断	18486259	RGD
enables antigen binding	IDA IDA: 通过直接分析推断	9252373	RGD
enables bHLH transcription factor binding	IPI IPI: 通过物理相互作用推断	11466227	RGD
enables chromatin DNA binding	IDA IDA: 通过直接分析推断	20702579	RGD
enables chromatin binding	IDA IDA: 通过直接分析推断	23652932	RGD
enables cis-regulatory region sequence-specific DNA binding	IDA IDA: 通过直接分析推断	19057620	RGD
enables histone acetyltransferase activity	IDA IDA: 通过直接分析推断	21307242	RGD
enables mitogen-activated protein kinase binding	IPI IPI: 通过物理相互作用推断	10363932	RGD
enables nuclear glucocorticoid receptor binding	IDA IDA: 通过直接分析推断	17884810	RGD
enables p53 binding	IPI IPI: 通过物理相互作用推断	21792911	RGD
enables peroxisome proliferator activated receptor binding	IDA IDA: 通过直接分析推断	12095700	RGD
enables promoter-specific chromatin binding	IDA IDA: 通过直接分析推断	21307242	RGD
enables protein antigen binding	IPI IPI: 通过物理相互作用推断	8985331	RGD
enables protein binding	IPI IPI: 通过物理相互作用推断	12970734	RGD
enables protein kinase binding	IPI IPI: 通过物理相互作用推断	20081228	RGD
enables protein-containing complex binding	IDA IDA: 通过直接分析推断	11755530	RGD
enables protein-containing complex binding	IPI IPI: 通过物理相互作用推断	15084519	RGD
enables transcription coactivator activity	IGI IGI: 通过遗传相互作用推断	10362258	RGD
enables transcription coregulator binding	IPI IPI: 通过物理相互作用推断	15598887	RGD

生物过程 GO 注释	逻辑证据	参考文献	来源
involved in cellular response to antibiotic	IEP IEP: 通过表达模式推断	22562121	RGD
involved in cellular response to cAMP	IEP IEP: 通过表达模式推断	20352046	RGD
involved in cellular response to dexamethasone stimulus	IEP IEP: 通过表达模式推断	22465009	RGD
involved in cellular response to glucose stimulus	IEP IEP: 通过表达模式推断	23211718	RGD
involved in cellular response to hydrogen peroxide	IEP IEP: 通过表达模式推断	17457521	RGD
involved in cellular response to interleukin-1	IMP IMP: 通过突变表型推断	18315570	RGD
involved in cellular response to mineralocorticoid stimulus	IEP IEP: 通过表达模式推断	22465009	RGD
involved in cellular response to nerve growth factor stimulus	IEP IEP: 通过表达模式推断	20399742	RGD
involved in cellular response to organic cyclic compound	IEP IEP: 通过表达模式推断	23632743	RGD
involved in cellular response to retinoic acid	IEP IEP: 通过表达模式推断	20711222	RGD
involved in cellular response to trichostatin A	IEP IEP: 通过表达模式推断	20094059	RGD
involved in cellular response to xenobiotic stimulus	IEP IEP: 通过表达模式推断	20888352	RGD
involved in digestive tract development	IEP IEP: 通过表达模式推断	17916272	RGD
involved in internal peptidyl-lysine acetylation	IMP IMP: 通过突变表型推断	22292478	RGD
involved in memory	IEP IEP: 通过表达模式推断	20811339	RGD
involved in negative regulation of cysteine-type endopeptidase activity involved in apoptotic process	IMP IMP: 通过突变表型推断	22562121	RGD
involved in negative regulation of miRNA metabolic process	IMP IMP: 通过突变表型推断	22367739	RGD
involved in peptidyl-lysine acetylation	IMP IMP: 通过突变表型推断	12724418	RGD
involved in positive regulation of DNA-binding transcription factor activity	IMP IMP: 通过突变表型推断	19057620	RGD
involved in positive regulation of axon extension	IMP IMP: 通过突变表型推断	19339625	RGD
involved in positive regulation of cell growth	IMP IMP: 通过突变表型推断	15593114	RGD
involved in positive regulation of cell growth involved in cardiac muscle cell development	IMP IMP: 通过突变表型推断	12724418	RGD
involved in positive regulation of cell size	IMP IMP: 通过突变表型推断	23211718	RGD
involved in positive regulation of cellular response to hypoxia	IMP IMP: 通过突变表型推断	18586071	RGD
involved in positive regulation of gene expression	IDA IDA: 通过直接分析推断	18438857	RGD
involved in positive regulation of gene expression	IMP IMP: 通过突变表型推断	18315570	RGD
involved in positive regulation of glycoprotein biosynthetic process	IMP IMP: 通过突变表型推断	17065349	RGD
involved in positive regulation of hydrogen peroxide-mediated programmed cell death	IMP IMP: 通过突变表型推断	23585551	RGD
involved in positive regulation of muscle atrophy	IMP IMP: 通过突变表型推断	22292478	RGD
involved in positive regulation of protein acetylation	IMP IMP: 通过突变表型推断	22566696	RGD
involved in positive regulation of protein phosphorylation	IMP IMP: 通过突变表型推断	22566696	RGD
involved in positive regulation of protein secretion	IMP IMP: 通过突变表型推断	12477714	RGD
involved in positive regulation of proteolysis	IMP IMP: 通过突变表型推断	16973938	RGD
involved in positive regulation of sarcomere organization	IMP IMP: 通过突变表型推断	12724418	RGD
involved in positive regulation of transcription by RNA polymerase II	IMP IMP: 通过突变表型推断	15598887	RGD
involved in positive regulation of translation	IMP IMP: 通过突变表型推断	12477714	RGD
involved in protein modification process	IMP IMP: 通过突变表型推断	22648458	RGD
involved in protein-DNA complex assembly	IDA IDA: 通过直接分析推断	9215639	RGD
involved in regulation of angiotensin metabolic process	IDA IDA: 通过直接分析推断	17495236	RGD
involved in response to calcium ion	IMP IMP: 通过突变表型推断	16000154	RGD
involved in response to cobalt ion	IEP IEP: 通过表达模式推断	18586071	RGD
involved in response to dexamethasone	IMP IMP: 通过突变表型推断	16973938	RGD
involved in response to estrogen	IEP IEP: 通过表达模式推断	15722556	RGD
involved in response to ethanol	IEP IEP: 通过表达模式推断	17208223	RGD
involved in response to fatty acid	IEP IEP: 通过表达模式推断	17916272	RGD
involved in response to glucose	IMP IMP: 通过突变表型推断	18413674	RGD
involved in response to hydrogen peroxide	IEP IEP: 通过表达模式推断	17457521	RGD
involved in response to hypoxia	IEP IEP: 通过表达模式推断	16000154	RGD
involved in response to organic cyclic compound	IEP IEP: 通过表达模式推断	18292809	RGD
involved in response to retinoic acid	IEP IEP: 通过表达模式推断	17164434	RGD
involved in response to tumor necrosis factor	IEP IEP: 通过表达模式推断	18438857	RGD
involved in response to xenobiotic stimulus	IMP IMP: 通过突变表型推断	15593114	RGD

细胞组分 GO 注释	逻辑证据	参考文献	来源
located in chromatin	IDA IDA: 通过直接分析推断	20702579	RGD
part of protein-DNA complex	IDA IDA: 通过直接分析推断	19765194	RGD
part of protein-DNA complex	IPI IPI: 通过物理相互作用推断	10362258	RGD
part of protein-containing complex	IDA IDA: 通过直接分析推断	21252119	RGD

EXP：通过实验结果推断 IDA：通过直接分析推断 IPI：通过物理相互作用推断 IMP：通过突变表型推断 IGI：通过遗传相互作用推断 IEP：通过表达模式推断

Ep300 蛋白结构

Med15

zf-TAZ

KIX

PABP-1234

PHA03247

Bromo_cbp_like

RING_CBP-p300

PHD_p300

HAT_KAT11

ZZ_CBP

zf-TAZ

Med15

Creb_binding

0
400
800
1200
1600
2000
2413 a.a.

蛋白主名

其他名称

histone acetyltransferase p300

LOW QUALITY PROTEIN: histone acetyltransferase p300

相关产品

Clinical Phase

生物活性分子 (5)

目录号	产品名	作用方式	纯度	Phase
HY-N0005	Curcumin		98.84%	Phase 4
HY-134964	CTB		99.93%	Phase 4
HY-111784	Inobrodib	Inhibitor	99.94%	Phase 2
HY-111422	PLX51107	Inhibitor	99.74%	Phase 2
HY-136938	NEO2734	Inhibitor	99.63%	Phase 1

Pre-clinical Phase

生物活性分子 (106)

Cat. No.	产品名	作用方式	纯度	是否罕见病
HY-107455	A-485	Inhibitor	99.87%	否
HY-13823	C646		99.78%	否
HY-14428	ICG-001		99.86%	否
HY-15826	SGC-CBP30	Inhibitor	99.83%	否
HY-134582	dCBP-1	Inhibitor	99.44%	否
HY-N2020	Anacardic Acid	Inhibitor	98.86%	否
HY-15887	MG 149		99.86%	否
HY-110127	NU9056		98.81%	否
HY-124696	PU139	Inhibitor	99.14%	否
HY-107569	Garcinol		≥99.0%	否
HY-100482	CPI-637	Inhibitor	99.94%	否
HY-136285	CPI-1612	Inhibitor	99.74%	否
HY-W013274	CPTH2		99.82%	否
HY-145765	JQAD1		98.70%	否
HY-116673	TTK21	Activator	99.39%	否
HY-19999A	PF-CBP1 hydrochloride	Inhibitor	99.99%	否
HY-124960	CTPB	Activator	≥99.0%	否
HY-19541	I-CBP112		98.20%	否
HY-100671	L002	Inhibitor	99.02%	否
HY-138539	CBP/p300 ligand 2		98.17%	否
HY-100726	GNE-272		99.76%	否
HY-101125	L-Moses	Inhibitor	99.97%	否
HY-10593	IQ 1	Modulator	99.13%	否
HY-100734	Histone Acetyltransferase Inhibitor II	Inhibitor	99.01%	否
HY-154984	JET-209	Degrader	98.07%	否
HY-132197	CBP/p300-IN-12	Inhibitor	99.70%	否
HY-N2345	Procyanidin B3	Inhibitor	99.63%	否
HY-138536	PROTAC CBP/P300 Degrader-1	Inhibitor	98.30%	否
HY-128876	CBP/p300-IN-3	Inhibitor	98.95%	否
HY-136920	CBP/p300-IN-8	Inhibitor	99.94%	否
HY-131035	Lys-CoA TFA	Inhibitor	99.42%	否
HY-158113	CBPD-409	Degrader	/	否
HY-147008	XP-524	Inhibitor	99.66%	否
HY-100697	TPOP146	Inhibitor	98.98%	否
HY-128875	CBP/p300-IN-10	Inhibitor	98.69%	否
HY-111420	CBP/p300-IN-1	Inhibitor	99.71%	否
HY-110263	EML 425	Inhibitor	98.16%	否
HY-152241	DS-9300	Inhibitor	99.83%	否
HY-134591	Thalidomide-NH-PEG4-COOH	Inducer	98.55%	否
HY-120290	PU141	Inhibitor	99.30%	否
HY-139108	DCH36_06		99.19%	否
HY-139148	UMB298	Inhibitor	99.11%	否
HY-153768	KAT modulator-1	Modulator	≥98.0%	否
HY-161369	CBPD-268	Degrader	/	否
HY-101125A	L-Moses dihydrochloride	Inhibitor	99.38%	否
HY-139707	Thalidomide-NH-CBP/p300 ligand 2	Degrader	98.55%	否
HY-101125B	D-Moses		/	否
HY-115539	Windorphen	Inhibitor	99.75%	否
HY-145386	(S,S)-CPI-1612		99.88%	否
HY-N0005S	Curcumin-d6		98.00%	否
HY-RS04405	EP300 Human Pre-designed siRNA Set A	Pre-designed Sets	/	否
HY-RS04406	Ep300 Mouse Pre-designed siRNA Set A	Pre-designed Sets	/	否
HY-149306	MS78		99.38%	否
HY-100132	CBP/p300-IN-5	Inhibitor	≥97.0%	否
HY-136285A	(R,R)-CPI-1612		99.49%	否
HY-146277A	CBP/p300-IN-19 hydrochloride	Inhibitor	/	否
HY-147290	NSC 694623	Inhibitor	99.36%	否
HY-151812	CBP/p300-IN-20	Inhibitor	98.03%	否
HY-P10238	MYBMIM	Inducer	99.44%	否
HY-134621	P300-IN-1	Inhibitor	/	否
HY-143443	DS17701585	Inhibitor	/	否
HY-W013274A	CPTH2 hydrochloride		/	否
HY-128597	BRD-IN-3	Inhibitor	/	否
HY-134592	Piperidine-GNE-049-N-Boc		98.82%	否
HY-141546	Pocenbrodib	Inhibitor	/	否
HY-121089	P300-IN-5		/	否
HY-124722	OHM1	Inhibitor	/	否
HY-128362	Ep300/CREBBP-IN-8	Inhibitor	/	否
HY-128363	Ep300/CREBBP-IN-2	Inhibitor	/	否
HY-128364	Ep300/CREBBP-IN-3	Inhibitor	/	否
HY-128367	Ep300/CREBBP-IN-4	Inhibitor	/	否
HY-128761	CBP/p300-IN-2	Inhibitor	/	否
HY-139861	CBP/p300-IN-14	Inhibitor	/	否
HY-143339	CBP/p300-IN-15	Inhibitor	/	否
HY-143440	CBP/p300-IN-16	Inhibitor	/	否
HY-143441	CBP/p300-IN-17	Inhibitor	/	否
HY-143442	CBP/p300-IN-18	Inhibitor	/	否
HY-146277	CBP/p300-IN-19	Inhibitor	/	否
HY-146445	P300 bromodomain-IN-1	Inhibitor	/	否
HY-147261	B026	Inhibitor	/	否
HY-155229	CBP/p300-IN-21	Inhibitor	/	否
HY-159131	PNSC928	Inhibitor	/	否
HY-159606	MS182	Inhibitor	/	否
HY-161250	Pomalidomide-NH-PEG6-amide-C2-CPI-1612		/	否
HY-161483	CBP/p300 ligand 3	Inhibitor	/	否
HY-161494	XYD190	Inhibitor	/	否
HY-161495	CBP/p300 ligand 4	Inhibitor	/	否
HY-161498	XYD198	Inhibitor	/	否
HY-161710	XYD129	Degrader	/	否
HY-161958	dCE-2		/	否
HY-161959	EP300/CBP ligand 1		/	否
HY-162128	Antitumor agent-130	Inhibitor	/	否
HY-162259	QC-182	Degrader	/	否
HY-164005	CBP/EP300 bromodomain receptor-IN-1	Inhibitor	/	否
HY-168148S	CZL-046	Inhibitor	/	否
HY-168201	MJP6412	Degrader	/	否
HY-RS04407	Ep300 Rat Pre-designed siRNA Set A	Pre-designed Sets	/	否
HY-123009	KCN1	Inhibitor	/	否
HY-123758	XDM-CBP	Inhibitor	/	否
HY-139804	CTK7A	Inhibitor	/	否
HY-160260	EP300/CBP-IN-1	Inhibitor	/	否
HY-160261S	EP300/CBP-IN-2	Inhibitor	/	否
HY-161711	CBP/p300 ligand 5		/	否
HY-161960	EP300/CBP ligand 2		/	否
HY-161961	Thalidomide-NH-C10-Boc		/	否
HY-19541A	I-CBP112 hydrochloride	Inhibitor	/	否

直系同源

种属	基因名	来源	基因 ID
Homo sapiens	Ep300	NCBI	NCBI:2033

MedChemExpress (MCE) 只为有资质的科研机构、医药企业基于科学研究或药证申报的用途提供医药研发服务，不为任何个人或者非科研性质的、非用于药证申报使用等其他用途提供服务。	站点地图隐私声明
沪ICP备15051369号-4 上海工商沪公网安备31011502019417 沪(浦)应急管危经许[2021]201709(QFYS) 营业执照（三证合一）
Copyright © 2013-2024 MedChemExpress. All Rights Reserved.

MedChemExpress (MCE) 只为有资质的科研机构、医药企业基于科学研究或药证申报的用途提供医药研发服务，不为任何个人或者非科研性质的、非用于药证申报使用等其他用途提供服务。

站点地图隐私声明

沪ICP备15051369号-4